ArticleCureus2024
In-Vitro Cytotoxicity, Apoptotic Property, and Gene Expression Changes Induced by Naringenin-7-O-Glucoside in Triple-Negative Breast Cancer.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The potential protective effect of naringenin against cadmium-induced toxicity in gingival cells.Odontology · 2026Article
- Effects of Naringenin in Preclinical Models of Breast Cancer.Biomolecules · 2026Review
- Mycochemistry, antioxidant activity and anticancer potentiality of ethyl acetate extract of Daldinia eschscholtzii against A549 lung cancer cell line.Scientific reports · 2025Article
- Morchella conica, Morchella esculenta and Morchella delicosa Induce Apoptosis in Breast and Colon Cancer Cell Lines via Pro-apoptotic and Anti-apoptotic Regulation.Chinese journal of integrative medicine · 2025Article
- UPLC-ESI-QTOF-MS/MS Profiling, Antioxidant, and Cytotoxicity Potentials of Marrubium vulgare L. Extracts: Experimental Analysis and Computational Validation.Chemistry & biodiversity · 2025Article
- LC-HRMS/MS-Guided Profiling and Biological Evaluation ofMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancer is one of the most significant health challenges demanding the expansion of effectual therapeutic methods. Triple-negative breast cancer (TNBC) is a form of aggressive cancer with inadequate therapeutic options which lacks the expression of certain hormones. MATERIALS AND
methodsThe present study investigates the potential of naringenin-7-O-glucoside, a flavanone glycoside extracted from
resultsMTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay studied the IC-50 of naringenin-7-O-glucoside to be 233.56 µg/µL, revealing the dose-dependent cytotoxicity with minimal effect on Vero cells. Extensive DNA fragmentation confirmed the apoptotic property. Furthermore, a significant downregulation of the epidermal growth factor receptor (EGFR) was noted in treated cells when equated to the control specimen of the sample.
conclusionTherefore, naringenin-7-O-glucoside can be a potential targeted therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.